DE69841037D1 - Charakterisierung von granulozytischer ehrlichia und methoden für ihre verwendung. - Google Patents

Charakterisierung von granulozytischer ehrlichia und methoden für ihre verwendung.

Info

Publication number
DE69841037D1
DE69841037D1 DE69841037T DE69841037T DE69841037D1 DE 69841037 D1 DE69841037 D1 DE 69841037D1 DE 69841037 T DE69841037 T DE 69841037T DE 69841037 T DE69841037 T DE 69841037T DE 69841037 D1 DE69841037 D1 DE 69841037D1
Authority
DE
Germany
Prior art keywords
proteins
nucleic acid
polypeptides
antibodies
acid molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69841037T
Other languages
English (en)
Inventor
Cheryl A Murphy
James Storey
Gerald A Beltz
Richard T Coughlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agenus Inc
Original Assignee
Antigenics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antigenics LLC filed Critical Antigenics LLC
Application granted granted Critical
Publication of DE69841037D1 publication Critical patent/DE69841037D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69841037T 1997-04-25 1998-04-24 Charakterisierung von granulozytischer ehrlichia und methoden für ihre verwendung. Expired - Lifetime DE69841037D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4493397P 1997-04-25 1997-04-25
PCT/US1998/008265 WO1998049313A2 (en) 1997-04-25 1998-04-24 Characterization of granulocytic ehrlichia and methods of use

Publications (1)

Publication Number Publication Date
DE69841037D1 true DE69841037D1 (de) 2009-09-17

Family

ID=21935120

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69841037T Expired - Lifetime DE69841037D1 (de) 1997-04-25 1998-04-24 Charakterisierung von granulozytischer ehrlichia und methoden für ihre verwendung.

Country Status (8)

Country Link
US (5) US6204252B1 (de)
EP (3) EP2060631A3 (de)
AT (1) ATE438657T1 (de)
AU (1) AU7256398A (de)
CA (1) CA2258277C (de)
DE (1) DE69841037D1 (de)
ES (1) ES2330393T3 (de)
WO (1) WO1998049313A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277381B1 (en) * 1997-03-21 2001-08-21 Corixa Corporation Compounds and methods for the diagnosis and treatment of Ehrlichia infection
US6673356B1 (en) 1997-03-21 2004-01-06 Corixa Corporation Compounds and methods for the diagnosis and treatment of ehrlichia infection
US6207169B1 (en) 1997-03-21 2001-03-27 Corixa Corporation Compounds and methods for the diagnosis and treatment of Ehrlichia infection
US6231869B1 (en) 1997-03-21 2001-05-15 Corixa Corporation Compounds and methods for the diagnosis and treatment of ehrlichia infection
EP2060631A3 (de) * 1997-04-25 2009-07-15 Aquila Biopharmaceuticals, Inc. Charakterisierung granulocytischer Ehrlichien und Verfahren zu ihrer Anwendung
EP1100917A1 (de) * 1998-07-28 2001-05-23 Aquila Biopharmaceuticals, Inc. Granulocytic ehrlichia genen und ihre verwendungen
US7407770B2 (en) * 2001-01-18 2008-08-05 Idexx Corporation Compositions and methods for detection of Ehrlichia canis and Ehrlichia chaffeensis antibodies
US7183060B2 (en) * 2005-02-22 2007-02-27 Idexx Laboratories, Inc. Peptides for detection of antibody to Ehrlichia ewingii
US20030129680A1 (en) * 2001-10-31 2003-07-10 O'connor Thomas Patrick Multi-analyte assay device
US20030194756A1 (en) * 2002-04-12 2003-10-16 O'connor Thomas Patrick Peptides for detection of antibody to Ehrlichia equi
US7087372B2 (en) * 2001-01-18 2006-08-08 Idexx Laboratories, Inc. Compositions and methods for detection of Ehrlichia canis and Ehrlichia chaffeensis antibodies
RU2527119C2 (ru) * 2006-01-05 2014-08-27 Медикал Инстилл Текнолоджис, Инк. Односторонний клапан, устройство и способ применения клапана
US7507789B2 (en) * 2007-04-09 2009-03-24 Idexx Laboratories, Inc. Detection of Anaplasma platys
US7964366B2 (en) * 2007-09-21 2011-06-21 Idexx Laboratories, Inc. Methods and compositions for detection of Ehrlichia chaffeensis (VLPT)
CA2700474C (en) * 2007-09-21 2016-10-04 Idexx Laboratories, Inc. Methods and compositions for detection of ehrlichia chaffeensis (p120)
US8158370B2 (en) 2007-11-27 2012-04-17 Idexx Laboratories, Inc. Anaplasma phagocytophilum (Aph) antigens and antibodies specific for Anaplasma
US8303959B2 (en) 2008-10-08 2012-11-06 Idexx Laboratories, Inc. Compositions and methods for detection of antibodies specific for Anaplasma phagocytophilum (Aph) and Anaplasma platys (Apl)
CA2781117C (en) * 2009-11-20 2019-05-28 Abaxis, Inc. Peptides, devices, and methods for the detection of ehrlichia antibodies
WO2013067448A2 (en) 2011-11-03 2013-05-10 Vca Antech Inc. Compositions and methods to detect various infectious organisms
WO2013113000A2 (en) 2012-01-26 2013-08-01 Luc Montagnier Detection of dna sequences as risk factors for hiv infection
US20130236898A1 (en) * 2012-03-09 2013-09-12 Charles A. Kallick Anaplasma FAMILY MEMBERS CAUSE A NUMBER OF BLOOD-BORNE DISEASES
CN105051541B (zh) 2012-10-11 2017-07-04 爱贝斯股份有限公司 用于检测埃里希体属抗体的肽、装置和方法
US9194870B2 (en) 2014-01-21 2015-11-24 Abaxis, Inc. Peptides, devices, and methods for the detection of Anaplasma antibodies
US9442112B2 (en) 2014-04-04 2016-09-13 Abaxis, Inc. Compositions and methods for identifying Ehrlichia species
WO2017078667A1 (en) * 2015-11-02 2017-05-11 Halliburton Energy Services, Inc. Reverse frac pack treatment

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
EP0247091B1 (de) 1985-11-01 1993-09-29 Xoma Corporation Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung
US5047540A (en) 1987-12-17 1991-09-10 Shionogi & Co., Ltd. Lipid derivatives
US5976860A (en) * 1995-06-06 1999-11-02 Aquila Biopharmaceuticals, Inc. Cell lines infected with granulocytic ehrlichia, vaccines, diagnostics and methods
US6284238B1 (en) 1995-06-06 2001-09-04 Aquila Biopharmaceuticals, Inc. Cell lines infected with granulocytic ehrlichia, vaccines, diagnostics and methods
US6015691A (en) 1996-05-31 2000-01-18 Research Development Foundation Immunodominant 120 kDa surface-exposed adhesion protein genes of Ehrlichia chaffeensis
JP2001502528A (ja) * 1996-10-01 2001-02-27 イェール ユニバーシティ ヒト顆粒球エールリヒア症の予防および診断のための組成物ならびに方法
US6207169B1 (en) 1997-03-21 2001-03-27 Corixa Corporation Compounds and methods for the diagnosis and treatment of Ehrlichia infection
US6277381B1 (en) 1997-03-21 2001-08-21 Corixa Corporation Compounds and methods for the diagnosis and treatment of Ehrlichia infection
US6231869B1 (en) 1997-03-21 2001-05-15 Corixa Corporation Compounds and methods for the diagnosis and treatment of ehrlichia infection
CA2258266A1 (en) 1997-04-25 1998-11-05 Aquila Biopharmaceuticals, Inc. Nucleic acids, proteins, and methods of use of granulocytic ehrlichia
EP2060631A3 (de) 1997-04-25 2009-07-15 Aquila Biopharmaceuticals, Inc. Charakterisierung granulocytischer Ehrlichien und Verfahren zu ihrer Anwendung
WO1999052370A1 (en) 1998-04-09 1999-10-21 The Ohio State Research Foundation Nucleic acids encoding outer membrane protein of human granulocytic ehrlichiosis agent
EP1100917A1 (de) 1998-07-28 2001-05-23 Aquila Biopharmaceuticals, Inc. Granulocytic ehrlichia genen und ihre verwendungen
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
BR112012027707A2 (pt) 2010-04-29 2018-05-08 Dfine Inc dispositivo médico para tratar tecido rígido
EP3198172B1 (de) 2014-09-22 2019-11-13 Schaeffler Technologies AG & Co. KG Hybridantriebsmodul mit einem dämpfer

Also Published As

Publication number Publication date
EP0915980B1 (de) 2009-08-05
CA2258277A1 (en) 1998-11-05
EP2060631A3 (de) 2009-07-15
US6204252B1 (en) 2001-03-20
US20120270232A1 (en) 2012-10-25
US8435495B2 (en) 2013-05-07
ATE438657T1 (de) 2009-08-15
US8093008B2 (en) 2012-01-10
WO1998049313A3 (en) 1999-01-14
EP0915980A2 (de) 1999-05-19
US20100088774A1 (en) 2010-04-08
WO1998049313A2 (en) 1998-11-05
US20110045605A1 (en) 2011-02-24
AU7256398A (en) 1998-11-24
EP2311957A1 (de) 2011-04-20
US8461323B2 (en) 2013-06-11
US7863434B2 (en) 2011-01-04
EP2060631A2 (de) 2009-05-20
ES2330393T3 (es) 2009-12-09
CA2258277C (en) 2013-08-13
US20120178102A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
DE69841037D1 (de) Charakterisierung von granulozytischer ehrlichia und methoden für ihre verwendung.
DE69840669D1 (de) Pca3, pca3-gene und verfahren zu ihrer verwendung
Harper et al. The purification of nerve growth factor from bovine seminal plasma. Biochemical characterization and partial amino acid sequence.
DK169724B1 (da) Fremgangsmåde til fremstilling af et polypeptidfragment af faktor VIII:C, DNA-sekvens, som koder herfor, og ekstrachromosomalt element indeholdende en sådan DNA-sekvens
DK0868519T3 (da) Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser
DE60026332D1 (de) Diagnose von einheimischer sprue/zöliakie mit hilfe von gliadinepitopen
ATE451390T1 (de) Polypeptide zur bindung an das b-lymphozyten- stimulatorische protein (blys)
ATE209356T1 (de) Ein verfahren zur bestimmung von kollagenfragmenten in körperflüssigkeiten, ein testkit und mittel zur durchführung des verfahrens, und seine verwendung zur feststellung von mit dem kollagenmetabolismus assoziierten störungen
WO1998057984A3 (en) Torsin, torsin genes, and methods of use
DE69535921D1 (de) Alk-7 (aktivin-rezeptor-ähnliche kinase), ein serin/threonin kinase rezeptor
Brock et al. Characterization of monoferric fragments obtained by tryptic cleavage of bovine transferrin
ATE350398T1 (de) Protein s polypeptide und deren verwendungen

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: JONES DAY RECHTSANWAELTE PATENTANWAELTE, 80538 MUE

8364 No opposition during term of opposition